Vogelxo is owned by Upsher Smith Labs.
Vogelxo contains Testosterone.
Vogelxo has a total of 3 drug patents out of which 0 drug patents have expired.
Vogelxo was authorised for market use on 04 June, 2014.
Vogelxo is available in gel, metered;transdermal, gel;transdermal dosage forms.
Vogelxo can be used as method for transdermal delivery of testosterone.
The generics of Vogelxo are possible to be released after 11 February, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785426 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) | |
US9662340 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) | |
US9295675 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 04 June, 2014
Treatment: Method for transdermal delivery of testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic